Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
China Manufacturing PMI Slips Into Contraction in January as Weak Demand Pressures Economy
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals
Japan Election Poll Signals Landslide Win for Sanae Takaichi, Raising Fiscal Policy Concerns 



